Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216024 | 0.89 | AR (0.50) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL16792415 | 0.84 | GAA (0.58) | ARHTR2ASLC6A4 | |
| SCHEMBL5949965 | 0.81 | AR (0.56) | ARSLC22A12 | |
| SCHEMBL11100867 | 0.81 | AR (0.53) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL19057971 | 0.80 | AR (0.47) | ARSLC22A12KCNH2 | |
| SCHEMBL2446602 | 0.78 | MAPT (0.50) | ARSLC22A12 | |
| SCHEMBL11752736 | 0.78 | AR (0.57) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL17407526 | 0.77 | AR (0.50) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL378894 | 0.76 | SLC22A12 (0.46) | ARSLC22A12 | |
| SCHEMBL5837296 | 0.75 | SLC22A12 (0.57) | ARSLC22A12HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790206-B2 | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790206-B2 | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2961744-B1 | INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | ARRAY BIOPHARMA INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20160002210-A1 | INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | ARRAY BIOPHARMA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002210-A1 | INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | ARRAY BIOPHARMA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014134313-A1 | INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | ARRAY BIOPHARMA INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| EP-1997809-B1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8518983-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1997810-B1 | Indazoles, benzotriazoles and N-analogs thereof as p38 kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2039685-B1 | Heterobicyclic compounds as P38 inhibitors | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1997809-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1981851-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2004078116-A9 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007089646-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089646-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-1606283-A4 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1606283-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004078116-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | AR 4017/4885SLC22A12 3886/4885HTR2A 3462/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | AR 4017/4885SLC22A12 3886/4885HTR2A 3462/4885 |
| US-20160002210-A1 | INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CYP3A7, CYP3A5, CYP3A43 | AR 3031/4885SLC22A12 3300/4885HTR2A 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.